Medical Disorders
Resources
Basic InformationLookupsLatest News
Time to Rethink Suicide Warnings on Labels for Anti-Seizure Meds?Smoggy Air Might Help Spur SinusitisIs It COVID? Early Signs May Differ by Age, GenderChanging Diets Mean More Americans Are Anemic NowHow the Delta Variant Is Changing the U.S. Forecast for COVID-19Regeneron Drug Approved to Help Prevent Severe COVID in Vulnerable After ExposureFull Approval of Pfizer COVID Vaccine Could Come in SeptemberSleep Apnea Doubles Odds for Sudden DeathNYC Becomes First to Require Vaccination Proof for Indoor ActivitiesCOVID Booster Shots to Be Offered to 32 Million BritsNo Sign COVID Raises Odds for Preterm Delivery, StillbirthsA Month Late, U.S. Finally Reaches 70% Vaccination MilestoneAHA News: Dangers of Life-Threatening Second Heart Attack May Be Highest Soon After the FirstAfter Nearly 9 Million Pfizer Shots for U.S. Teens, Serious Side Effects Rare: CDCHow Did the Pandemic Affect Cancer Clinical Trials?New Data Shows the Power of COVID VaccinesTroubling Rise Seen in Both COVID, RSV Cases Among ChildrenTake This Refresher on Skin Safety in Summer SunAll Sunglasses Not Equal When it Comes to Eye ProtectionTeens' Heart Risk From COVID Far Exceeds That of Vaccination: StudyCould COVID-19 Accelerate Alzheimer's Symptoms?New Data Details Dangers of Delta Variant, Even for the VaccinatedCDC Now Says Vaccinated Should Be Tested After COVID Exposure, Even Without SymptomsWhy Strokes Can Affect Women, Men DifferentlyMore Than Half of Americans Plagued by Back, Leg PainPfizer Says 3rd Shot of Vaccine Boosts COVID ProtectionVitamin D May Lower Black Women's Odds for COVID-19Primary Care Doctors Often Miss Heart Failure in Women, Black PatientsBogus Info on Cancer Common Online, and It Can HarmDelta Variant Spreads More Easily, Causing CDC Change on Indoor MaskingSevere COVID for People Under 45: Who's Most at Risk?The Heat Is On: Staying Safe When Temperatures SoarWho's Most Likely to Refuse a COVID Vaccine?Second COVID Shot Safe in Folks Who Had Allergic Reaction to FirstHigh Blood Pressure: Which Drug Works Best for You?Pfizer, Moderna to Expand Vaccine Studies in Young ChildrenFederal, State Moves Begin to Mandate COVID Vaccines for WorkersCan COVID Transmit Easily on Crowded School Buses?Worried About Delta-Linked 'Breakthrough' Infections? Experts Explain the RisksMajor Medical Groups Call for Mandatory COVID Vaccination for Health WorkersU.S. to Stick With International Travel RestrictionsSurvey Finds U.S. Parents Split on COVID Vaccination for Kids Under 12Most Unvaccinated Americans Want to Stay That Way: PollIt's Tick Season: Protect Yourself From Lyme DiseaseHigh-Tech Exoskeletons Improve Bowel Function in People With Spinal Cord Injury'Superbug' Fungus Spreads Among Vulnerable in Two U.S. CitiesVaccinations Start to Climb in States Hit Hard by Delta VariantBiden Says Full Approval for COVID Vaccines Coming SoonPfizer Vaccine Offers 88% Protection Against Delta Variant, But 2 Doses NeededSecret Weapon: Why the 2nd Dose of Pfizer Vaccine Is So Crucial
Questions and AnswersVideosLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

Could a Type of Statin Raise Dementia Risks?

HealthDay News
by By Amy Norton HealthDay Reporter
Updated: Jun 15th 2021

new article illustration

TUESDAY, June 15, 2021 (HealthDay News) -- Certain cholesterol-lowering drugs might speed dementia in some older adults whose memories are starting to fail, a small, preliminary study suggests.

The researchers found that of 300 older adults with mildly impaired thinking and memory, those using "lipophilic" statins were more likely to develop dementia over the next eight years.

Lipophilic statins include such widely used medications as simvastatin (Zocor), atorvastatin (Lipitor) and lovastatin (Altoprev).

They're considered lipophilic because they are attracted to fat and can cross into many body tissues, including the brain. That's in contrast to hydrophilic statins — like rosuvastatin (Crestor) and pravastatin (Pravachol) — which act mainly in the liver.

In this study, there was no link between those statins and increased dementia risk.

The findings do not prove that lipophilic statins directly raise dementia risk, experts cautioned. But they add to a conflicting body of evidence on statins and brain function.

"This adds another piece to a complicated puzzle," said Dan Berlau, a professor of pharmacy at Regis University in Denver, who was not involved in the new investigation but studies memory and disorders of the brain.

He said that high cholesterol in middle-age is linked to a higher risk of dementia later on. As for whether taking statins might curb that risk, Berlau said, studies have mostly come to either of two conclusions: the drugs show no effect, or a protective one.

If statins are protective, one reason may be their cardiovascular benefits: They cut "bad" cholesterol and help prevent fatty plaques from clogging arteries that supply the brain.

But other types of cholesterol medications have not been tied to lower dementia risk, Berlau noted, which hints at something special about statins. Animal research has suggested the drugs might reduce Alzheimer's-related "plaque" buildup or counter inflammation in the brain, for instance.

Yet there is also evidence tying statins to short-term problems with cognition (thinking and memory), Berlau noted. Some statin users have developed cognitive problems while taking the drugs — issues that go away when the medication is stopped. (Statin labels now carry a warning about that.)

It's been theorized that in some people, lipophilic statins might lower cholesterol levels in the brain below the threshold needed for normal cognition.

According to Berlau, it's difficult to know how to square that with large population studies showing a lower dementia risk among statin users, most of whom were on lipophilic medications.

This latest study dug deeper, said project leader Prasanna Padmanabham, of the molecular and medical pharmacology student research program at the University of California, Los Angeles (UCLA).

The researchers separated older adults into groups based on three factors: their initial cognitive status; initial cholesterol levels; and the type of statin they were using.

Of 303 participants with mild cognitive impairment, 200 had total cholesterol levels that were normal or near-normal. It turned out that lipophilic statins were linked to higher dementia risk only among those individuals.

In that group, 24% of lipophilic statin users developed dementia over the next eight years, versus 10% of people not using any statin and 11% of hydrophilic statin users.

In addition, brain scans revealed certain changes linked to dementia among lipophilic statin users, but not people on hydrophilic statins, the researchers said.

Padmanabham was scheduled to present the findings at the annual meeting of the Society of Nuclear Medicine and Molecular Imaging, held online June 11 to 15, and the findings were recently published in a supplement of the Journal of Nuclear Medicine.

No one should toss their statins based on these findings, cautioned senior researcher Dr. Dan Silverman, a professor of molecular and medical pharmacology at UCLA.

For one, he said, the elevated dementia risk was seen only in a select group of people.

And in general, the decision to use statins — and the choice of medication — depends on various factors, Silverman added.

Those factors include an individual's personal risk of cardiovascular disease and whether there are any co-existing medical conditions, like kidney disease.

That said, if people with mild cognitive impairment and fairly low cholesterol levels are on a lipophilic statin, they might want to talk to their doctor about a switch, Silverman said.

Hydrophilic statins can help keep blood cholesterol in check, he noted, without crossing into the brain.

It's not clear why lipophilic statins carried a higher dementia risk only among study participants with lower cholesterol. But it's possible, Silverman said, that in those with higher cholesterol, the benefits of the medications outweighed any potential ill effects on the brain.

Berlau echoed the message that patients should not abandon their statins. "We have lots of evidence tying statins to a protective effect against dementia," he noted.

And based on their well-established cardiovascular benefits, Berlau said, "I'd still recommend them."

More information

The Bright Focus Foundation has more on statins and dementia.

SOURCES: Prasanna Padmanabham, student research program, molecular and medical pharmacology, University of California, Los Angeles; Dan Silverman, MD, PhD, professor, department of molecular and medical pharmacology, University of California, Los Angeles; Dan Berlau, PhD, professor, School of Pharmacy, Regis University, Denver; presentation, Society of Nuclear Medicine and Molecular Imaging annual meeting, June 11 to 15, 2021, online




Facebook

Amazon Smile

 

Children and Adult services are available now with no wait time.  

Please contact HBH at 860-548-0101, option 2.

 


powered by centersite dot net